Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-18T11:12:27.328Z Has data issue: false hasContentIssue false
  • English
  • Français

The zoonotic potential of Mycobacterium avium ssp. paratuberculosis: a systematic review and meta-analyses of the evidence

Published online by Cambridge University Press:  20 May 2015

L. A. WADDELL ,
A. RAJIĆ ,
K. D. C. STÄRK  and
S. A. McEWEN
L. A. WADDELL*
Affiliation:
University of Guelph, Department of Population Medicine, Guelph, ON, Canada Laboratory for Foodborne Zoonoses, Public Health Agency of Canada, Guelph, ON, Canada
A. RAJIĆ
Affiliation:
Agriculture and Consumer Protection Department, Food and Agriculture Organization, Rome, Italy
K. D. C. STÄRK
Affiliation:
Royal Veterinary College, North Mymms, Hertfordshire, UK
S. A. McEWEN
Affiliation:
University of Guelph, Department of Population Medicine, Guelph, ON, Canada
*
*Author for correspondence: Ms. L. A. Waddell, Public Health Agency of Canada, 160 Research Lane, Unit 206, Guelph, Ontario N1G 5B2, Canada. (Email: lisa_waddell@phac-aspc.gc.ca)
Rights & Permissions [Opens in a new window]

Summary

This systematic review–meta-analysis appraises and summarizes all the available research (128 papers) on the zoonotic potential of Mycobacterium avium ssp. paratuberculosis. The latter has been debated for a century due to pathogenic and clinical similarities between Johne's disease in ruminants and Crohn's disease (108 studies) in humans and recently for involvement in other human diseases; human immunodeficiency virus (HIV) infection (2), sarcoidosis (3), diabetes mellitus type 1 (T1DM) (7) and type 2 (3), multiple sclerosis (5) and Hashimoto's thyroiditis (2). Meta-analytical results indicated a significant positive association, consistently across different laboratory methods for Crohn's disease [odds ratio (OR) range 4·26–8·44], T1DM (OR range 2·91–9·95) and multiple sclerosis (OR range 6·5–7·99). The latter two and the thyroiditis hypothesis require further investigation to confirm the association. Meta-regression of Crohn's disease studies using DNA detection methods indicated that choice of primers and sampling frame (e.g. general population vs. hospital-based sample) explained a significant proportion of heterogeneity. Other epidemiological studies demonstrated a lack of association between high-risk occupations and development of Crohn's disease. Due to knowledge gaps in understanding the role of M. paratuberculosis in the development or progression of human disease, the evidence at present is not strong enough to inform the potential public health impact of M. paratuberculosis exposure.

Keywords

Crohn's disease (CD)diabetesJohne's diseasemeta-analysismultiple sclerosisMycobacterium avium ssp. paratuberculosisparatuberculosissystematic reviewthyroiditis
Type
Review
Information
Epidemiology & Infection , Volume 143 , Issue 15 , November 2015 , pp. 3135 - 3157
Check for updates
Copyright
Copyright © Cambridge University Press and the Government of Canada, represented by the Public Health Agency of Canada 2015 

INTRODUCTION

The zoonotic potential of Mycobacterium avium ssp. paratuberculosis has been debated for a century since it was first suggested that Crohn's disease (CD) is pathologically and clinically analogous to Johne's disease [Reference Behr and Collins1–Reference Grant3]. Research on this association has increased over the last 30 years, from the first isolation of M. paratuberculosis in a CD patient by Chiodini et al. and the subsequently published review of evidence supporting the potential association in 1989 [Reference Chiodini4, Reference Chiodini5]. A detailed history of this research can be found in a number of papers and books on this topic [Reference Behr and Collins1, Reference Naser6]. More recently M. paratuberculosis has been hypothesized to play a role in the development or progression of a number of other human diseases including HIV infection, sarcoidosis, diabetes mellitus type 1 (T1DM) and type 2 (T2DM), multiple sclerosis and Hashimoto's thyroiditis mainly on the basis of immune dysfunction hypotheses [Reference Nacy and Buckley7–Reference Sechi11].

These chronic diseases have no known cure and together they affect several hundred million people globally. CD is a chronic debilitating idiopathic gastroenteritis that affects 1–2 million people worldwide [Reference Naser6, Reference Molodecky12]. Similarly diabetes mellitus (T1DM, an autoimmune condition where insulin is not produced by the pancreas and T2DM, a condition where cells do not respond to normal levels of insulin) affects 382 million people worldwide [13]. Multiple sclerosis is a complex autoimmune disease of the central nervous system that affects an estimated 1·3 million people worldwide [Reference Cossu, Masala and Sechi8, 14]. Hashimoto's thyroiditis (chronic lymphocytic thyroiditis) is an autoimmune disease in which the thyroid gland is attacked by a variety of cell- and antibody-mediated immune processes and affects 7·2–36 million people worldwide [15]. Sarcoidosis is an unexplained abnormal collection of inflammatory cells in organs that usually resolves without medical intervention except in rare cases where it can become a chronic condition; it is estimated to affect 0·07–2·9 million people worldwide [Reference Erdal16].

Many of the hypotheses on the potential zoonotic role of M. paratuberculosis draw on pathological and clinical similarities (analogy) between Johne's disease in ruminants and CD in humans, and M. paratuberculosis’ ability to cause natural infection in non-ruminants, e.g. dogs, rabbits, non-human primates [Reference Behr and Collins1, Reference El-Zaatari, Osato and Graham17]. The evidence for M. paratuberculosis’ role in human disease to date points to multiple interacting factors such as dysregulation of the immune system (e.g. genetic predisposition, immune-mediated tissue injury) and environmental exposures, such as diet and exposure to pathogens or changes in the normal gut microflora that when combined may cause the disease [Reference Behr and Collins1, Reference Naser6]. Molecular mimicry has also been suggested to have a role in the pathogenesis of CD, T1DM and multiple sclerosis, proposing that an infectious agent like M. paratuberculosis has antigenic elements similar to the host that can induce autoimmunity [Reference Cossu, Masala and Sechi8].

This systematic review (SR) tabulates the global evidence and presents meta-analytical summaries of the current knowledge underpinning the public health question, ‘Is M. paratuberculosis zoonotic?’ [Reference Young18, Reference Sargeant19]. This SR updates a previous SR covering primary research until the end of 2005 [Reference Waddell20] and evaluates agreement or changes in research knowledge published over the last 9 years [Reference Naser6, Reference Feller21–Reference Eltholth23]. The scope of this SR is extended beyond potential association between M. paratuberculosis and CD, and includes all human diseases that have been linked with M. paratuberculosis. To the best of our knowledge no other SR has evaluated evidence on M. paratuberculosis as an infectious disease candidate for multiple human diseases.

The objectives of this SR/meta-analysis (MA) are: (1) to identify and characterize the research investigating an association between human diseases and M. paratuberculosis, (2) to estimate the strength of the association(s) and agreement across epidemiological studies using various detection methods and, (3) evaluate strengths, weaknesses, and gaps in current evidence. Knowledge gaps and future research priorities to address public health questions are highlighted in the Discussion.

METHODS

Protocol

An a-priori developed and pre-tested SR protocol (Supplementary material: Appendix 1) included the study question, sub-questions, definitions, procedure for literature search, study inclusion/exclusion criteria and checklists for conducting relevance screening, basic characterization, methodological assessment and data extraction on relevant primary research, following the general principles of SR methodology [Reference Young18, Reference Sargeant24, Reference Rajic, Young and McEwen25]. All primary research investigating the zoonotic potential of M. paratuberculosis and human disease, and published in English or French languages was analysed. This included case-control studies investigating associations between M. paratuberculosis and human disease, studies looking at the association between Johne's disease in ruminants and human disease and molecular epidemiology studies examining the relatedness of human and animal isolates of M. paratuberculosis. Relevant expertise within our SR research team included M. paratuberculosis, food safety, risk assessment, epidemiology, library, and synthesis research (e.g. SR and MA) methods.

Search strategy

The original search strategy by Waddell et al. [Reference Waddell20] was simplified and updated based on recent improvements in electronic bibliographic databases and the number of databases was reduced based on the results of unpublished research on search sensitivity and specificity [Reference Harris26]. The following search algorithms were implemented on 27 September 2013 in three databases, Pubmed, Scopus and Current Contents:

((johne disease) OR (johne's disease) OR (johne* disease) OR paratuberculosis OR (mycobacterium paratuberculosis) OR (mycobacteria AND crohn*)) AND ((crohn* disease) OR (crohn disease) OR (crohn's disease) OR (inflammatory bowel disease) OR (inflammatory bowel diseases) OR diabetes OR sarcoidosis OR lymphadenitis OR immunocompromis* OR (AIDS) OR (Blau syndrome) OR (multiple sclerosis) OR thyroiditis)

For research on CD, publication date was set from 1 January 2005 onward without any other restrictions or filters as this aspect was already investigated in the previous SR covering research to 2005 [Reference Waddell20]. For all other diseases we did not impose any restrictions. Citations retrieved from all databases were imported into reference management software Procite v. 5.0.3 (ISI Researchsoft, 1995) and de-duplicated. Search verification was twofold; first, reference lists of review articles [Reference Naser6, Reference Sohal27–Reference Kaevska and Hruska31] and three SRs published on M. paratuberculosis [Reference Feller21–Reference Eltholth23] were searched by hand. Second we identified all citations relevant to this SR during relevance screening for a scoping review on sources of M. paratuberculosis being conducted at the same time to identify any potentially missed citations. Any potentially relevant unique citation identified by search verification was added to the SR at the relevance screening stage and processed through all SR tools as appropriate.

Abstract and article-level relevance screening and study characterization

Through initial abstract-based screening (Fig. 1) by two reviewers working independently, all potentially relevant primary research in English or French investigating the zoonotic potential of M. paratuberculosis was identified. Non-primary research studies (e.g. narrative reviews) or primary research studies outside of the scope were intentionally excluded. All citations deemed relevant at the abstract-based screening level were procured as full articles. Abstract screening was conducted by two independent reviewers using standardized and pre-tested checklists. Reviewer agreement (κ ⩾ 0·8) was evaluated using 30 abstracts. Conflicts were resolved through consensus between respective reviewers and if this was not possible, by a third team member.

Fig. 1. Flow chart describing the movement of 3560 citations, the exclusion of 3432 and the inclusion of 128 studies through the systematic review process. HIV, Human immunodeficiency virus; T1DM/T2DM, diabetes mellitus type 1/type 2; CC, case-control study; CR case report or case series.

Risk of bias, GRADE and data extraction

Full paper assessment using a direct modification of the risk of bias and Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria endorsed by the Cochrane collaboration was undertaken on each study and GRADE criteria were summarized for groups of studies contributing to each MA [Reference Guyatt32–35]. The risk-of-bias assessment aims to assess the internal validity of the study which informs of the GRADE criteria [Reference Higgins, Altman, Higgins and Green33, 34]. GRADE criteria are summarized across groups of similar studies to indicate the level of confidence in the current evidence [35]. The 1- to 4-star grading system indicates: high confidence that the effect estimate is close to the true effect (****); moderate confidence in the effect estimate, but future studies may be substantially different (***); limited confidence in the estimate of effect, the true effect may be substantially different (**); and very little confidence in the estimate of effect, the true effect is likely to be substantially different (*) [Reference Balshem36–Reference Schunemann38]. The data extraction tool (Supplementary material, Appendix 1) aimed to efficiently capture the pertinent information and results needed for MA from each study. Both steps were conducted by two reviewers working independently and conflicts were resolved by consensus.

Study management and data analysis

All SR stages, i.e. relevance screening, risk-of-bias assessment and data extraction, were conducted in Microsoft Excel 2010 (Microsoft Corp., USA). The data were analysed descriptively [Stata v. 13 (StataCorp., USA)], followed by random-effects MA of selected subgroups of data in Comprehensive Meta-analysis Software v. 2 (Biostat, USA), which employs the method of moments weighting procedure [Reference DerSimonian and Laird39]. Heterogeneity, or across study variation, was quantified by Higgins’ I 2 [Reference Higgins40]. Meta-regression was conducted in Stata v. 13 using the random-effects maximum likelihood (REML) weighting procedure and changes in T 2, an estimate of τ 2 or true standard variance across studies was used to quantify the amount of heterogeneity that was explained by covariates in the model [Reference Borenstein41]. Where appropriate, homogenous MAs with more than 10 lines of data were evaluated for publication bias by Begg's and Egger's [Reference Egger42, Reference Begg and Mazumdar43] tests. If publication bias was detected, Duval & Tweedie's trim-and-fill method was used to estimate the potential impact on the estimate and conclusions of the MA [Reference Duval and Tweedie44]. Results with high heterogeneity are still reported in this review as we believe that they are more informative than reporting a range of results. However, we caution readers to use heterogeneous results carefully as the source of heterogeneity is unknown and future research may significantly change the results of the MA.

RESULTS

Description of relevant studies

The updated electronic search yielded 876 citations after de-duplication and Figure 1 shows the progression of papers through the SR process. A total of 128 articles, 60 added in this update 2005–2013, are included and summarized in this SR (Supplementary Appendix 2, list of included studies). All studies were published in English and originated from the USA/Canada (30%), Europe (52·6%), Asia (9·8%), Australia and New Zealand (6·0%) and the Middle East (0·8%). The top three publishing countries were: USA (25·6%, n = 34), Italy (18·8%, n = 25, 16 from a single research group) and UK (12%, n = 16). The first relevant study was published in 1980; however, the majority (65%) of the studies summarized in this SR were published since 2000. Studies were mainly observational (95%) and case control was the most common study design (87%). Patients with CD were the focus of 80% of studies, with human immunodeficiency virus (HIV) (1·6%), sarcoidosis (2·4%), T1DM (5·5%), T2DM (2·4%), multiple sclerosis (5·5%), Hashimoto's thyroiditis (1·6%) and human (disease not reported in a few prevalence surveys and molecular epidemiology studies) (3·9%) also captured in this SR.

Studies were categorized in three main groups; (1) those that evaluated the association of M. paratuberculosis with human disease, (2) the association between Johne's disease in ruminants and human disease (mainly CD), and (3) molecular epidemiology studies investigating the relatedness of M. paratuberculosis isolates from different species to evaluate evidence for strain sharing and zoonotic potential. There were 116 studies that contributed 163 lines of data summarized in Tables 1–4 on the association of M. paratuberculosis with CD (96 studies), HIV (2), sarcoidosis (3), T1DM (7), T2DM (3), multiple sclerosis (5), Hashimoto's thyroiditis (2). Five studies with varying study designs and objectives looked at evidence for an association between Johne's disease and CD including two cross-sectional studies examining high exposure occupations and CD [Reference Jones45, Reference Qual46], one case series that tested newly diagnosed CD patients over 5 years for M. paratuberculosis [Reference Wagner47] and two challenge trials that investigated whether M. paratuberculosis isolates from humans could produce Johne's disease in goats [Reference Van Kruiningen48, Reference Gitnick49]. Seven molecular epidemiology studies looked at the relatedness of M. paratuberculosis isolates from a variety of species including humans [Reference Singh50–Reference Francois, Krishnamoorthy and Elion56].

Table 1. Summary of findings: association of direct detection of Mycobacterium paratuberculosis and Crohn's disease in humans

OR Odds ratio; CI, Confidence interval; MA, meta-analysis; PCR, polymerase chain reaction; I 2, measure of heterogeneity.

GRADE: GRADE Working Group grades of evidence (see explanations): **** high quality: very confident the true effect lies close the estimate of effect;

*** moderate quality: moderate confidence the true effect is likely close to the estimate of effect, but is possibly substantially different; ** low quality: limited confidence in the estimate of effect, the true effect may be substantially different; * very low quality: very little confidence in the estimate of effect, the true effect is likely substantially different from the estimate of effect.

The potential association of M. paratuberculosis with Crohn's disease was investigated in 67 studies by culture, PCR or hybridization to identify M. paratuberculosis in samples (tissue, blood, faeces). Forty-nine out of 67 studies provided usable data and are included in the meta-analyses presented in this table. The 18 excluded either had no M. paratuberculosis isolated or 100% of samples were positive. The methodological soundness of included studies was poor [case-control (66) and cross-sectional (1)] and there was a lot of unexplained heterogeneity in the PCR and hybridization studies. Many studies did not detect a significant association between M. paratuberculosis and Crohn's disease; however, the MA results were significant for both the culture and PCR results. Due to the heterogeneity and low methodological quality of the included studies, future research will likely alter the estimates from this summary-of-findings table.

Table 2. Summary of findings: association of Mycobacterium paratuberculosis and Crohn's disease in humans by ELISA

OR, Odds ratio; CI, Confidence interval; SDS, sodium dodecyl sulfate; r recombinant protein; † results of a random effect meta-analysis;ELISA, enzyme-linked immunosorbent assay; PPA, protoplasmic antigen; PPD, purified protein derivative; I 2, measure of heterogeneity; ASCA, anti-Saccharomyces cerevisiae antibody; MAP, Mycobacterium avium ssp. paratuberculosis; PCR, polymerase chain reaction; CD, Crohn's disease; LAM, lipoarabinomannan; AhpC, alkyl hydroperoxide reductase C; AhpD, alkyl hydroperoxide reductase D; PtpA, protein tyrosine phosphatase A.

GRADE: GRADE Working Group grades of evidence (see explanations): **** high quality: very confident the true effect lies close the estimate of effect; *** moderate quality: moderate confidence the true effect is likely close to the estimate of effect, but is possibly substantially different; ** low quality: limited confidence in the estimate of effect, the true effect may be substantially different; * very low quality: very little confidence in the estimate of effect, the true effect is likely substantially different from the estimate of effect.

The potential association of M. paratuberculosis with CD was investigated in 30 studies that used ELISA to determine if the immune response to a M. paratuberculosis antigen was different in CD compared to controls. All studies except one used blood samples as well as gut lavage samples. Target antigens ranged from non-specific PPA or LAM preparations to targeted pure recombinant proteins. Nineteen of the 30 studies provided usable data and are included in the meta-analyses presented in this table and Figure 2. The three studies excluded from this table had no reaction [Reference Kallinowski63], analysed inflammatory bowel disease patients as one group [Reference Juste85] or did not test the control group [Reference McFadden and Houdayer84]. The methodological soundness of included studies was poor (case-control), there was a lot of heterogeneity in the methods and the target antigens. Many studies individually did not detect a significant association between M. paratuberculosis and CD; however, overall the meta-analyses detected a significant association and the ELISA results were similar to those from culture and PCR studies. Due to the heterogeneity and low methodological quality of the included studies, future research will likely alter the estimates from this summary-of-findings table.

Table 3. Summary of findings: association of Mycobacterium paratuberculosis and Crohn's disease in humans using lymphocyte/cytokine assays

CD, Crohn's disease; PBMC, peripheral blood macrophage cells; AhpC, alkyl hydroperoxide reductase C; AhpD, alkyl hydroperoxide reductase D; PPD, purified protein derivative; PBL, peripheral blood lymphocytes; MAP, Mycobacterium avium ssp. paratuberculosis; LPL, lamina propria lymphocytes; IL, interleukin.

GRADE: GRADE Working Group grades of evidence (see explanations): **** high quality: very confident the true effect lies close the estimate of effect; *** moderate quality: moderate confidence the true effect is likely close to the estimate of effect, but is possibly substantially different; ** low quality: limited confidence in the estimate of effect, the true effect may be substantially different; * very low quality: very little confidence in the estimate of effect, the true effect is likely substantially different from the estimate of effect.

The potential association of M. paratuberculosis with CD was investigated in 11 studies that examined lymphocyte proliferation or cytokine production in response to M. paratuberculosis. Various cytokines were evaluated, most studies did not have extractable data, and data was displayed graphically in the papers. The methodological soundness of included studies was poor (case-control), there was a lot of heterogeneity in the methods and most are not directly comparable to each other. Many studies individually did not detect a significant difference in the immune reaction of CD samples vs. controls. Due to the heterogeneity and low methodological quality of the included studies, future research will likely alter the estimates and conclusions in this table.

Table 4. Summary of findings: association of Mycobacterium paratuberculosis and diseases other than Crohn's disease in humans

OR, Odds ratio; CI, Confidence interval; P, Prevalence results (+/-); C, results on a continuous scale; † results of a random effect meta-analysis; PCR, polymerase chain reaction; MAP Mycobacterium avium ssp. paratuberculosis.

GRADE: GRADE Working Group grades of evidence (see explanations): **** high quality: very confident the true effect lies close the estimate of effect; *** moderate quality: moderate confidence the true effect is likely close to the estimate of effect, but is possibly substantially different; ** low quality: limited confidence in the estimate of effect, the true effect may be substantially different; * very low quality: very little confidence in the estimate of effect, the true effect is likely substantially different from the estimate of effect.

The potential association of M. paratuberculosis with diseases other than Crohn's disease was investigated in 20 studies (2 HIV, 2 sarcoidosis, 7 T1DM, 3 T2DM, 5 multiple sclerosis and 2 Hashimoto's thyroiditis). Methodological soundness of included studies was poor (case-control, case report and case series), and most were examining immune reactions, thus examining the association indirectly. T1DM and multiple sclerosis show consistent, statistically significant results across studies and outcomes. The hypothesis of M. paratuberculosis involvement in Hashimoto's thyroiditis requires investigation. No statistically significant association was reported for T2DM, sarcoidosis or HIV. Thus, additional studies on any of these diseases could change the conclusions and would likely alter the estimates from this summary-of-findings table.

Excluded: Reid & Chiodini (1993) [Reference Reid and Chiodini140] on sarcoidosis; excluded because the antigens were not specific to M. paratuberculosis.

M. paratuberculosis association with CD

One hundred and eight studies examined the association between M. paratuberculosis bacteria or antigen with CD, and of these 96 were case-control studies. Sixty-seven case-control studies directly detected the presence of M. paratuberculosis from human samples; faeces, blood, or intestinal tissue using culture [confirmed by staining, histology and polymerase chain reaction (PCR)], PCR (single and nested) or hybridization. Of these 67 studies, 18 were excluded from summarization and analysis because they did not have any M. paratuberculosis-positive results (17 studies) or they had 100% positive samples in both groups (1) [Reference Sasikala57–Reference Cellier74]. There were 15 studies (19 lines) that reported detection of live M. paratuberculosis by culture with an overall odds ratio (OR) of 8·44 [95% confidence interval (CI) 4·51–15·83, I 2 = 42%; Table 1]. Similarly, across 40 studies (45 lines) that detected M. paratuberculosis DNA (44) or RNA (1) in samples by PCR and hybridization the overall OR of 5·24 (95% CI 3·33–8·25, I 2 = 83%) showed a heterogeneous positive association. Investigating reasons for this heterogeneity by subgroup analysis of PCR primers and using meta-regression for selected explanatory variables indicated that the origin of the sampling frame (hospital, clinic, general population or isolate library) accounted for a significant proportion (33%) of heterogeneity. Substantial variation in OR by different detection methods was observed across studies, particularly in PCR primers used (many developed in-house); the results are synthesized by primer in Table 1. Several primers yielded non-significant results across several studies. No other a-priori selected explanatory variable accounted for the heterogeneity, including choice of control group (healthy, other intestinal disease or ulcerative colitis), M. paratuberculosis detection methods (direct PCR, nested PCR, hybridization), sample type (faeces, blood or intestinal tissue: biopsy vs. resected), sample state (fresh, frozen, paraffin embedded), primer size, GRADE (down grade or no grade change) or risk of bias (low, unclear, high) designation. In direct detection studies, 27 reported a significant positive association, 15 a positive non-significant association, five a negative non-significant association, and two a significant negative association. A further 17 did not isolate any M. paratuberculosis and one reported 100% samples positive; these studies could not assess association. Since most studies were secondary-based case-control designs, confidence in this evidence is moderate to weak (GRADE ** to ***).

Thirty-eight studies (54 lines of data) used evidence of immune response by ELISA or immunoblot and/or examined differing results in lymphocyte or cytokine assays in CD patients compared to controls. Similar to the results for detection of M. paratuberculosis, 16 ELISA studies (22 lines) used a number of antigens, demonstrated high heterogeneity between studies and had an overall OR of 4·26 (95% CI 2·45–7·38, I 2 = 81%; Fig. 2). The two studies (four lines) that reported results from sodium dodecyl sulfate (SDS) immunoblot had an overall OR of 25·01 (95% CI 12·55–49·85, I 2 = 43%; Table 2). Four other studies reported significant associations with reactivity to M. paratuberculosis [Reference Shin75–Reference Bach78], four reported no significant association [Reference Lee79–Reference Walmsley82] and one reported contradictory associations between children and adults with CD [Reference Verdier83] (Table 2). Three studies were excluded from this summary because no reaction to M. paratuberculosis occurred [Reference Kallinowski63], only CD patients were tested [Reference McFadden and Houdayer84] and results were not reported separately for CD and ulcerative colitis patients [Reference Juste85]. Eleven studies (14 lines) examined differences in lymphocyte proliferation or cytokine production in response to M. paratuberculosis between CD patients and controls (Table 3). A significant association between CD patients and controls was reported in two of four studies using lymphocyte proliferation where peripheral blood lymphocytes (PBL) were suppressed and there was increased suppression cell function in one study [Reference Ebert86] and higher T-cell proliferation in the other for CD patients compared to controls [Reference Olsen87]. Eight studies examined cytokine production, three found no association and the remaining five reported lower IFN-γ and higher IL-4, IL-2, TNF-α in CD patients compared to controls. Only IL-10, examined in four studies, had conflicting results in two studies [Reference Campos88, Reference Sibartie89] and non-significant results in two studies [Reference Olsen76, Reference Clancy90], Table 3. Overall studies examining immune reactions to M. paratuberculosis in CD patients and controls reported significant positive association in 22 studies and non-significant results in 15 studies (14 positive and one negative).

Fig. 2. Random-effects meta-analysis of 16 case-control studies (I 2 = 81%) that examined the association of immune reactions measured by ELISA to M. paratuberculosis in Crohn's disease patients compared to controls. MAP, M. paratuberculosis; PPD, purified protein derivative; PPA, protoplasmic antigen, HSP, heat shock protein; AHP, alkyl hydroperoxide reductase; GSD, glycosyl transferase; HBHA, heparin-binding haemagglutinin.

A small number of non-case control observational studies and experiments relevant to the evaluation of the association between M. paratuberculosis and CD were identified. As shown in Table 5, two cross-sectional surveys did not find an association between CD and high-risk occupations such as dairy farming and practising veterinary medicine on large animals [Reference Jones45, Reference Qual46]. The third study was a case series of newly diagnosed CD patients that were followed and periodically tested for M. paratuberculosis over 5 years. In this study of 13 patients, three always tested positive, three were always negative and the other seven tested both positive and negative over time [Reference Wagner47]. Two studies were challenge trials where M. paratuberculosis strains isolated from humans were used to experimentally challenge young goats; however, neither trial was of long enough duration to produce clinical Johne's disease in the goats and only one trial described Johne's disease-like lesions [Reference Van Kruiningen48, Reference Gitnick49].

Table 5. Summary of findings: association of Mycobacterium paratuberculosis and Crohn's disease in humans by non-case-control study design

JD, Johne's disease; CD, Crohn's disease.

GRADE: GRADE Working Group grades of evidence (see explanations): **** high quality: very confident the true effect lies close the estimate of effect; *** moderate quality: moderate confidence the true effect is likely close to the estimate of effect, but is possibly substantially different; ** low quality: limited confidence in the estimate of effect, the true effect may be substantially different; * very low quality: very little confidence in the estimate of effect, the true effect is likely substantially different from the estimate of effect.

There were a limited number of observational studies that looked at an association with JD, and results from prevalence and longitudinal prevalence surveys.

Molecular epidemiology studies (n=7) make up the last type of relevant evidence by comparing isolates from different species and humans, some linked by geography and time, while others are from diverse sources around the world (Table 6). Globally, human isolates were considered most likely to be of bovine origin [Reference Wynne51–Reference Singh55], although the human isolates from two studies were also closely related to ovine type M. paratuberculosis [Reference Ghadiali52, Reference Motiwala53]. In addition, two studies from India reported that a high proportion of human isolates were bison type, results so far unique to India [Reference Francois, Krishnamoorthy and Elion56, Reference Singh91]. Wynne et al. [Reference Wynne51] described human isolates that matched the bovine isolate from samples taken at the same time in the same region, lending evidence for potential sharing of M. paratuberculosis between species.

Table 6. Summary of findings: molecular epidemiology evidence for the relatedness of Mycobacterium paratuberculosis from various animal species and humans

PCR-REA, Polymerase chain reaction-restriction enzyme analysis; CD, Crohn's disease; nIBD, non-inflammatory bowel disease; CGH, comparative genome hybridization; UC, ulcerative colitis; MPIL, multiplex PCR of IS900 integration loci; AFLP, amplified fragment length polymorphism; RFLP, restriction fragment length polymorphism.

GRADE: GRADE Working Group grades of evidence (see explanations): **** high quality, very confident the true effect lies close the estimate of effect; *** moderate quality: moderate confidence the true effect is likely close to the estimate of effect, but is possibly substantially different; ** low quality: limited confidence in the estimate of effect, the true effect may be substantially different; * very low quality: very little confidence in the estimate of effect, the true effect is likely substantially different from the estimate of effect.

Only 7 studies have examined the relatedness of M. paratuberculosis isolated from humans and animals. Many studies used an isolate library for their sampling frame, thus, are representative of a geographic area or point in time. Most human isolates were reported to cluster with bovine isolates, however some from Ghadaili [Reference Ghadiali52] and Motiwala [Reference Motiwala53] also clustered with ovine isolates and those from India were most likely to be bison type (Singh [Reference Singh50, Reference Francois, Krishnamoorthy and Elion56]). Overall a close relationship between human and animal strains was reported, but it is still unclear if there is limit strain diversity in human M. paratuberculosis. Further research should focus on representative sampling and further evaluation of strain diversity from human isolates. Due to heterogeneity in the molecular methods and limited extrapolation of the samples evaluated future studies may completely change the conclusions of this summary-of-findings table.

M. paratuberculosis association with human disease other than CD

The majority of research on M. paratuberculosis’ association with human disease has focused on CD described in the previous section; however, there are 20 studies (16 case-controls, three case reports and one case series) that investigated the potential association of M. paratuberculosis with other human diseases (Table 4). The evidence within these studies was deemed very weak (GRADE *), meaning future research may completely change the conclusions of current research. The exception was T1DM that was recently investigated in seven studies (from the USA and Italy) all of which agreed an association may exist, providing weak but consistent evidence (GRADE * to **) for an association (Table 4).

Random-effects MA of the association between T1DM and direct detection of M. paratuberculosis by PCR yielded an OR of 2·91 (95% CI 1·33–6·33) [Reference Paccagnini10, Reference Rosu92–Reference Naser94] and for the association between T1DM and detection of an immune reaction to M. paratuberculosis by ELISA yielded an OR of 9·95 (95% CI 5·75–17·25) [Reference Rosu92–Reference Masala95] two additional ELISA studies not included in the MA reported significantly higher reactions to M. paratuberbulosis in T1DM patients compared to controls [Reference Cossu96, Reference Cossu97]. Since our SR search, a study from India has reported finding no association with T1DM [Reference Rani98].

Recently, very weak evidence for a significant association with multiple sclerosis and M. paratuberculosis has been investigated in Sardinia, Italy, which is a unique isolated population that has very high levels of autoimmune disease [Reference Cossu99, Reference Frau100], three studies [Reference Cossu101–Reference Cossu103] were removed from this summary as they are preliminary data to Frau et al. [Reference Cossu100] to avoid double-counting results (Dr Sechi, personal communication). The generalizability of this association needs to be investigated. A hypothesis was presented for an association between M. paratuberculosis infection and Hashimoto's thyroiditis based on two case reports involving one family [Reference Sisto9, Reference D'Amore104]. This has been further supported by a study published after our SR search, also from Italy, that provides evidence for an association with M. paratuberculosis [Reference Rosu105]; however, future research on other populations is needed to provide further evidence for this hypothesis. By contrast, there was no observed association between M. paratuberculosis infection with T2DM [Reference Rosu92, Reference Naser94, Reference Rosu106] and non-significant results from HIV [Reference Richter107, Reference Naser108] and sarcoidosis studies [Reference El-Zaatari109–Reference Lisby, Milman and Jacobsen111]. The latter two diseases were examined over a decade ago and no further studies examining this association have been published.

DISCUSSION

This SR is an in-depth analysis of the current global evidence underpinning the zoonotic potential of M. paratuberculosis. The 60 studies added to this review since the original search in 2005 [Reference Waddell20], indicate that research on the potential association with human disease is still very active and not limited to CD, but now includes a possible association with T1DM, multiple sclerosis and Hashimoto's thyroiditis that will require further research to confirm or refute the existence of a true association. The MAs of case-control studies on CD conducted on different test categories demonstrate agreement in the direction and relative strength of the association. However, there is a general lack of evidence that explains the role of M. paratuberculosis in CD and the wide variation in control or disease group M. paratuberculosis prevalence across studies, indications that the evidence required to understand the role, if any, of M. paratuberculosis in the initiation or progression of CD has not been realized. Thus, we re-confirm our previous conclusions [Reference Waddell20] that while the zoonotic potential of M. paratuberculosis cannot be ignored, due to important knowledge gaps in understanding its role and importance in the development or progression of human disease, its impact on public health cannot yet be quantified or described.

The strongest evidence for an association between M. paratuberculosis and human disease (mainly from studies on CD) arises from the studies that identify culturable organisms or DNA in appropriate samples; these studies have been conducted in increasing numbers since the original SR [Reference Waddell20]. Moreover, these studies were based on CD populations around the world and included faecal and blood samples in addition to tissue samples (intestinal biopsy and resection). This group of 18 studies was homogenous, demonstrated culturable M. paratuberculosis in the samples and thus yielded the highest confidence in the MA conclusions. However, there were a number of methodological issues with this group of studies that ranked the risk of bias in eight of them (five published since 2005) as high or unclear due to inappropriate sampling frames and poor reporting of study design. There are many widely accepted guidelines for study design and reporting (e.g. STROBE statement for reporting observational studies) that if adhered to, should improve the utility and transparency of future studies [Reference Ebrahim and Clarke112–Reference Vandenbroucke114].

Studies that used PCR and hybridization to detect M. paratuberculosis demonstrate the existence of M. paratuberculosis DNA (or RNA) in the sample. From this information we cannot know if the detected DNA is from a culturable organism, but we can compare the frequency of occurrence between disease and control groups. There were 57 PCR and hybridization studies, of which 22 were published since 2005. There was a lot of heterogeneity in the results of these studies from sample preparation to the vast numbers of primers used across studies, including many that have been developed ‘in house’ and never validated. It should also be noted that some more widely used primers have produced only insignificant results for an association with CD, thus we encourage future researchers to consider using primers that have been validated to improve the interpretation and comparability across studies.

In the meta-regression significant heterogeneity was explained by accounting for the origin of the sampling frame (i.e. hospital vs. general population). The association between M. paratuberculosis and CD was only significant for case-control studies that used samples from hospitalized patients and tissue library samples, whereas samples taken from outpatient clinics and the general population showed no relationship. There are several possible reasons for this, including selection bias and different sampling strategies or the type of sample, which was not significant in the univariate meta-regression; however, outpatient studies were more likely to use faecal and blood samples and have less control over the medical history of the controls which could lead to misclassification. Alternatively, the outpatient findings may reflect a more realistic association than the secondary-based case-control studies. The potential discrepancy in results between primary- and secondary-based studies will require further appropriately designed research.

Across case-control studies there was considerable variability in the prevalence of M. paratuberculosis prevalence in both the control and diseased groups ranging from 0% to 100%. This inconsistency has not been explained in the literature, but may be due to true differences in prevalence, differences in test sensitivity and detection limits or even variation in sampling strategy. To complicate this further, a small cohort study by Wagner et al. [Reference Wagner47] demonstrated that some CD patients intermittently test positive for M. paratuberculosis by PCR over time and infection may persist despite antimicrobial treatment. Research has not adequately addressed the effects of stage of disease and various treatments on the outcome of M. paratuberculosis testing and there is conflicting results on the relationship between M. paratuberculosis test results and CD activity status (measure of disease symptoms occurring at the time of sample collection) [Reference Ebert86, Reference Olsen87, Reference Del Prete115–Reference Kobayashi, Blaser and Brown117].

Studies that have shown an immune reaction to M. paratuberculosis provide evidence of prior exposure to the organism, and there is some evidence that there is a different immune response to M. paratuberculosis in CD patients compared to controls. Overall, these studies provided evidence for an association at a similar magnitude to the direct detection studies, but individually, there were many studies that did not detect a significant association between M. paratuberculosis and human disease. Many of the lymphocyte and cytokine assay studies were working on the hypothesis that there is immune dysfunction in CD patients and they were attempting to demonstrate up-regulation or down-regulation of the inflammatory pathways. This type of work is also being done for Johne's disease with some recent successes in the identification of M. paratuberculosis activated immune pathways that lead to the clinical signs [Reference Bannantine and Bermudez118]. Across these studies there was little consistency in their approach, lymphocyte populations, antigens or cytokines, thus limiting the overall conclusions that can be drawn.

Evidence for the ecological association between Johne's disease and CD is limited and not strong. The two cross-sectional studies failed to find an association between high M. paratuberculosis exposure populations and CD [Reference Jones45, Reference Qual46]. A recent molecular epidemiology study demonstrated evidence of M. paratuberculosis strain sharing between human and bovine isolates from the same geographical range [Reference Wynne51]. This is in agreement with other studies that showed human isolates were more likely to be bovine type than ovine type M. paratuberculosis, including a recently published genome sequence from human breast milk [Reference Wynne51, Reference Motiwala53–Reference Singh55, Reference Bannantine119]. Exceptions to these results are studies from India, where high proportion of an indigenous bison-type M. paratuberculosis, classified as newly evolved, have been reported [Reference Singh50, Reference Francois, Krishnamoorthy and Elion56, Reference Singh120–Reference Sohal122]. The potential public health implications of high prevalence of M. paratuberculosis in humans from India remain unclear [Reference Singh50]. Future molecular research should seek to confirm the extent that different M. paratuberculosis strains may be shared between different species.

There are several limitations to the retrospective case-control studies, case series and case reports which make up 90% of the research captured in this SR. These include an inability to evaluate temporal relationships and M. paratuberculosis exposure [Reference Dohoo, Martin and Stryn123]. Selection bias can easily occur in case and control selection and the studies lack generalizability to the whole population [Reference Dohoo, Martin and Stryn123]. However, due to the long incubation period of mycobacterial infections and therefore long latency between likely exposure and disease, and the comparative low incidence of some of the studied diseases (particularly CD), case-control is often the only feasible study design [Reference Dohoo, Martin and Stryn123]. While we have gained more evidence over the past seven years, there is still a lack of longitudinal prospective cohort or case-controls studies in high exposure or low disease populations, respectively, that may help us understand the potential relationship between exposure to M. paratuberculosis and disease outcomes. Ultimately, we are still lacking an understanding of M. paratuberculosis’ role in CD or other human diseases.

This updated SR summarizes the largely epidemiological research on the association between M. paratuberculosis and human disease (mainly CD). It highlights important knowledge gaps such as understanding M. paratuberculosis's role in disease and the relationship between exposure and disease development in humans. Although we presented some strong and consistent MA results of the association between M. paratuberculosis and human disease; the variability in M. paratuberculosis prevalence in controls and diseased groups and a lack of understanding whether some or all CD is caused or propagated by M. paratuberculosis are important knowledge gaps. These are the reasons for the lack of support for recommending further interventions against human exposure to M. paratuberculosis beyond what the dairy and ruminant industries have already developed for animal health and economic reasons. Thus, M. paratuberculosis may have a role in human disease; however the evidence is not strong enough to inform the potential public health impact of M. paratuberculosis exposure.

SUPPLEMENTARY MATERIAL

For supplementary material accompanying this paper visit http://dx.doi.org/10.1017/S095026881500076.

ACKNOWLEDGEMENTS

The authors thank the reviewers, and Zee Leung, Vi Nguyen, Shannon Harding, Miranda Galati, Judy Greig, and Ian Young for their participation in this project. Thanks are due to the Public Health Agency of Canada for their support in conducting this research and the library staff for obtaining articles.

DECLARATION OF INTEREST

None.

References

REFERENCES

1. Behr, MA, Collins, DM (eds). Paratuberculosis: Organism, Disease, Control, 1st edn. UK: CAB International, 2010.CrossRefGoogle Scholar
2. Biet, F, et al. Zoonotic aspects of Mycobacterium bovis and Mycobacterium avium-intracellulare complex (MAC). Veterinary Research 2005; 36: 411–436.CrossRefGoogle ScholarPubMed
3. Grant, IR. Zoonotic potential of Mycobacterium avium ssp. paratuberculosis: the current position. Journal of Applied Microbiology 2005; 98: 1282–1293.CrossRefGoogle ScholarPubMed
4. Chiodini, RJ, et al. Spheroplastic phase of mycobacteria isolated from patients with Crohn's disease. Journal of Clinical Microbiology 1986; 24: 357–363.Google ScholarPubMed
5. Chiodini, RJ. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clinical Microbiology Reviews 1989; 2: 90–117.Google ScholarPubMed
6. Naser, SA, et al. Mycobacterium avium subspecies paratuberculosis causes Crohn's disease in some inflammatory bowel disease patients. World Journal of Gastroenterology 2014; 20: 7403–7415.Google ScholarPubMed
7. Nacy, C, Buckley, M. Mycobacterium avium paratuberculosis: Infrequent Human Pathogen or Public Health Threat? American Academy of Microbiology, Washington DC, USA, 2008.Google Scholar
8. Cossu, D, Masala, S, Sechi, LA. A Sardinian map for multiple sclerosis. Future Microbiology 2013; 8: 223–232.CrossRefGoogle ScholarPubMed
9. Sisto, M, et al. Proposing a relationship between Mycobacterium avium subspecies paratuberculosis infection and Hashimoto's thyroiditis. Scandinavian Journal of Infectious Diseases 2010; 42: 787–790.CrossRefGoogle ScholarPubMed
10. Paccagnini, D, et al. Linking chronic infection and autoimmune diseases: Mycobacterium avium subspecies paratuberculosis, SLC11A1 polymorphisms and type-1 diabetes mellitus. PLoS ONE 2009; 4: e7109.Google ScholarPubMed
11. Sechi, LA, et al. Mycobacterium avium subspecies paratuberculosis bacteremia in type 1 diabetes mellitus: an infectious trigger? Clinical Infectious Disease 2008; 46: 148–149.CrossRefGoogle ScholarPubMed
12. Molodecky, NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46–54.CrossRefGoogle ScholarPubMed
13. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. International Diabetes Federation, 2013.Google Scholar
14. World Health Organisation. Atlas Multiple Sclerosis Resources in the World 2008. Geneva, Switzerland: World Health Organization, 2008.Google Scholar
15. Chronic thyroiditis (Hashimoto's disease) (http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001409/). Accessed 25 July 2014.Google Scholar
16. Erdal, BS, et al. Unexpectedly high prevalence of sarcoidosis in a representative U.S. Metropolitan population. Respiratory Medicine 2012; 106: 893–899.CrossRefGoogle Scholar
17. El-Zaatari, FA, Osato, MS, Graham, DY. Etiology of Crohn's disease: the role of Mycobacterium avium paratuberculosis . Trends in Molecular Medicine 2001; 7: 247–252.CrossRefGoogle ScholarPubMed
18. Young, I, et al. The application of knowledge synthesis methods in agri-food public health: recent advancements, challenges and opportunities. Preventive Veterinary Medicine 2014; 113: 339–355.CrossRefGoogle ScholarPubMed
19. Sargeant, J, et al. The process of systematic review and its application in agri-food public-health. Preventative Veterinary Medicine 2006; 75: 141–151.CrossRefGoogle ScholarPubMed
20. Waddell, LA, et al. The zoonotic potential of Mycobacterium avium spp. paratuberculosis: a systematic review. Canadian Journal of Public Health 2008; 99: 145–155.CrossRefGoogle ScholarPubMed
21. Feller, M, et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infectious Diseases 2007; 7: 607–613.CrossRefGoogle ScholarPubMed
22. Abubakar, I, et al. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis. Inflammatory Bowel Disease 2008; 14: 401–410.CrossRefGoogle ScholarPubMed
23. Eltholth, MM, et al. Contamination of food products with Mycobacterium avium paratuberculosis: a systematic review. Journal of Applied Microbiology 2009; 107: 1061–1071.CrossRefGoogle ScholarPubMed
24. Sargeant, J, et al. Conducting Systematic Reviews in Agri-Food Public Health, 2005 (http://www.angelfire.com/co4/civph/). Accessed 25 November 2014.Google Scholar
25. Rajic, A, Young, I, McEwen, SA. Improving the utilization of research knowledge in agri-food public health: a mixed-method review of knowledge translation and transfer. Foodborne Pathogens and Disease 2013; 10: 397–412.CrossRefGoogle ScholarPubMed
26. Harris, J, et al. Evaluating the effectiveness of search strategies for systematic reviews in zoonotic public health. In: Canadian Cochrane Symposium Proceedings. Edmonton: Canadian Cochrane. 2008, pp. 36.Google Scholar
27. Sohal, JS, et al. Strain diversity within Mycobacterium avium subspecies paratuberculosis – a review. Indian Journal of Experimental Biology 2010; 48: 7–16.Google ScholarPubMed
28. Rosenfeld, G, Bressler, B. Mycobacterium avium paratuberculosis and the etiology of Crohn's disease: a review of the controversy from the clinician's perspective. Canadian Journal of Gastroenterology 2010; 24: 619–624.CrossRefGoogle ScholarPubMed
29. Pierce, ES. Ulcerative colitis and Crohn's disease: is Mycobacterium avium subspecies paratuberculosis the common villain? Gut Pathogens 2010; 2: 21.CrossRefGoogle ScholarPubMed
30. Lalande, J, Behr, MA. Mycobacteria in Crohn's disease: how innate immune deficiency may result in chronic inflammation. Expert Review of Clinical Immunology 2010; 6: 633–641.CrossRefGoogle ScholarPubMed
31. Kaevska, M, Hruska, K. Analysis of publications on paratuberculosis from 1995 to 2009 with emphasis on the period from 2005 to 2009. Veterinární Medicína 2010; 55: 43–54.CrossRefGoogle Scholar
32. Guyatt, G, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011; 64: 383–394.CrossRefGoogle ScholarPubMed
33. Higgins, J, Altman, D. Assessing risk of bias in included studies, Chapter 8. In: Higgins, JPT, Green, S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0·1 (updated September 2008). The Cochrane Collaboration, 2008.CrossRefGoogle Scholar
34. Cochrane Handbook of Systematic Reviews and Interventions (http://handbook.cochrane.org/). Accessed 24 June 2014.Google Scholar
35. GRADE guidelines. best practices using the GRADE framework (http://www.gradeworkinggroup.org/publications/jce_series.htm). Accessed 24 June 2014.Google Scholar
36. Balshem, H, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011; 64: 401–406.CrossRefGoogle ScholarPubMed
37. Guyatt, GH, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011; 64: 1311–1316.CrossRefGoogle ScholarPubMed
38. Schunemann, H, et al. The GRADE approach and Bradford Hill's criteria for causation. Journal of Epidemiology and Community Health 2010; 65: 392–395.CrossRefGoogle ScholarPubMed
39. DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177–188.Google ScholarPubMed
40. Higgins, JP, et al. Measuring inconsistency in meta-analyses. British Medical Journal 2003; 327: 557–560.CrossRefGoogle ScholarPubMed
41. Borenstein, M, et al. Introduction to Meta-Analysis . Chichester/Hoboken: John Wiley & Sons, 2009.CrossRefGoogle Scholar
42. Egger, M, et al. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997; 315: 629–634.Google ScholarPubMed
43. Begg, CB, Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.CrossRefGoogle Scholar
44. Duval, S, Tweedie, R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455–463.CrossRefGoogle ScholarPubMed
45. Jones, PH, et al. Crohn's disease in people exposed to clinical cases of bovine paratuberculosis . Epidemiology and Infection 2006; 134: 49–56.CrossRefGoogle ScholarPubMed
46. Qual, DA, et al. Lack of association between the occurrence of Crohn's disease and occupational exposure to dairy and beef cattle herds infected with Mycobacterium avium subspecies paratuberculosis . Journal of Dairy Science 2010; 93: 2371–2376.CrossRefGoogle ScholarPubMed
47. Wagner, J, et al. Mycobacterium avium subspecies paratuberculosis in children with early-onset Crohn's disease: a longitudinal follow-up study. Inflammatory Bowel Disease 2011; 17: 1825–1826.CrossRefGoogle ScholarPubMed
48. Van Kruiningen, HJ, et al. Experimental disease in infant goats induced by a Mycobacterium isolated from a patient with Crohn's disease. A preliminary report. Digestive Diseases and Sciences 1986; 31: 1351–1360.CrossRefGoogle ScholarPubMed
49. Gitnick, G, et al. Preliminary report on isolation of mycobacteria from patients with Crohn's disease. Digestive Diseases and Sciences 1989; 34: 925–932.CrossRefGoogle ScholarPubMed
50. Singh, AV, et al. Genotype profiles of Mycobacterium avium subspecies paratuberculosis recovered from suspected and Crohn's disease patients in India. Journal of Communicable Diseases 2010; 42: 91–100.Google ScholarPubMed
51. Wynne, JW, et al. Exploring the zoonotic potential of Mycobacterium avium subspecies paratuberculosis through comparative genomics. PLoS ONE 2011; 6: e22171.CrossRefGoogle ScholarPubMed
52. Ghadiali, AH, et al. Mycobacterium avium subsp. paratuberculosis strains isolated from Crohn's disease patients and animal species exhibit similar polymorphic locus patterns. Journal of Clinical Microbiology 2004; 42: 5345–5348.CrossRefGoogle ScholarPubMed
53. Motiwala, AS, et al. Molecular epidemiology of Mycobacterium avium subsp. paratuberculosis: evidence for limited strain diversity, strain sharing, and identification of unique targets for diagnosis. Journal of Clinical Microbiology 2003; 41: 2015–2026.CrossRefGoogle ScholarPubMed
54. Whittington, RJ, et al. Molecular epidemiology of Mycobacterium avium subsp. paratuberculosis: IS900 restriction fragment length polymorphism and IS1311 polymorphism analyses of isolates from animals and a human in Australia. Journal of Clinical Microbiology 2000; 38: 3240–3248.CrossRefGoogle Scholar
55. Francois, B, Krishnamoorthy, R, Elion, J. Comparative study of Mycobacterium paratuberculosis strains isolated from Crohn's disease and Johne's disease using restriction fragment length polymorphism and arbitrarily primed polymerase chain reaction. Epidemiology and Infection 1997; 118: 227–233.CrossRefGoogle ScholarPubMed
56. Singh, SV, et al. Genotype profiles of Mycobacterium avium subspecies paratuberculosis isolates recovered from animals, commercial milk, and human beings in North India. International Journal of Infectious Diseases 2009; 13: e221–7.CrossRefGoogle ScholarPubMed
57. Sasikala, M, et al. Absence of Mycobacterium avium ssp. paratuberculosis-specific IS900 sequence in intestinal biopsy tissues of Indian patients with Crohn's disease. Indian Journal of Gastroenterology 2009; 28: 169–174.CrossRefGoogle Scholar
58. Magin, WS, Van Kruiningen, HJ, Colombel, JF. Immunohistochemical search for viral and bacterial antigens in Crohn's disease. Journal of Crohn's and Colitis 2013; 7: 161–166.CrossRefGoogle ScholarPubMed
59. Bibiloni, R, et al. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. Journal of Medical Microbiology 2006; 55: 1141–1149.CrossRefGoogle ScholarPubMed
60. Kanazawa, K, et al. Absence of Mycobacterium paratuberculosis DNA in intestinal tissues from Crohn's disease by nested polymerase chain reaction. Journal of Gastroenterology 1999; 34: 200–206.Google ScholarPubMed
61. Gibson, J, et al. Looking for Mycobacterium paratuberculosis DNA by polymerase chain reaction (PCR) in orofacial granulomatosis (OFG) and oral Crohn's disease tissue in an Irish population. Irish Medical Journal 2000; 93: 218.Google Scholar
62. Fujita, H, et al. Quantitative analysis of bacterial DNA from Mycobacteria spp., Bacteroides vulgatus, and Escherichia coli in tissue samples from patients with inflammatory bowel diseases. Journal of Gastroenterology 2002; 37: 509–516.CrossRefGoogle ScholarPubMed
63. Kallinowski, F, et al. Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease. Hepatogastroenterology 1998; 45: 1552–1558.Google ScholarPubMed
64. Chiba, M, et al. No Mycobacterium paratuberculosis detected in intestinal tissue, including Peyer's patches and lymph follicles, of Crohn's disease. Journal of Gastroenterology 1998; 33: 482–487.CrossRefGoogle ScholarPubMed
65. Al-Shamali, M, et al. A multiplex polymerase chain reaction assay for the detection of Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Scandinavian Journal of Gastroenterology 1997; 32: 819–823.CrossRefGoogle ScholarPubMed
66. Dumonceau, JM, et al. No Mycobacterium paratuberculosis found in Crohn's disease using polymerase chain reaction. Digestive Diseases and Sciences 1996; 41: 421–426.CrossRefGoogle ScholarPubMed
67. Frank, TS, Cook, SM. Analysis of paraffin sections of Crohn's disease for Mycobacterium paratuberculosis using polymerase chain reaction. Modern Pathology 1996; 9: 32–35.Google ScholarPubMed
68. Tanaka, K, et al. Mycobacterium paratuberculosis and Crohn's disease. Gut 1991; 32: 43–45.CrossRefGoogle ScholarPubMed
69. Butcher, PD, McFadden, JJ, Hermon-Taylor, J. Investigation of mycobacteria in Crohn's disease tissue by Southern blotting and DNA hybridisation with cloned mycobacterial genomic DNA probes from a Crohn's disease isolated mycobacteria. Gut 1988; 29: 1222–1228.CrossRefGoogle ScholarPubMed
70. Graham, DY, Markesich, DC, Yoshimura, HH. Mycobacteria and inflammatory bowel disease. Results of culture. Gastroenterology 1987; 92: 436–442.CrossRefGoogle ScholarPubMed
71. Sechi, LA, et al. Relationship between Crohn's disease, infection with Mycobacterium avium subspecies paratuberculosis and SLC11A1 gene polymorphisms in Sardinian patients. World Journal of Gastroenterology 2006; 12: 7161–7164.CrossRefGoogle ScholarPubMed
72. Lozano-Leon, A, Barreiro-de, Acosta, Dominguez-Munoz, JE. Absence of Mycobacterium avium subspecies paratuberculosis in Crohn's disease patients. Inflammatory Bowel Diseases 2006; 12: 1190–1192.CrossRefGoogle ScholarPubMed
73. Ellingson, JL, et al. Absence of Mycobacterium avium subspecies paratuberculosis components from Crohn's disease intestinal biopsy tissues. Clinical Medical Research 2003; 1: 217–226.CrossRefGoogle ScholarPubMed
74. Cellier, C, et al. Mycobacterium paratuberculosis and Mycobacterium avium subsp. silvaticum DNA cannot be detected by PCR in Crohn's disease tissue. Gastroenterologie Clinique et Biologique 1998; 22: 675–678.Google ScholarPubMed
75. Shin, AR, et al. Identification of seroreactive proteins in the culture filtrate antigen of Mycobacterium avium ssp. paratuberculosis human isolates to sera from Crohn's disease patients. FEMS Immunology and Medical Microbiology 2010; 58: 128–137.CrossRefGoogle ScholarPubMed
76. Olsen, I, et al. Elevated antibody responses in patients with Crohn's disease against a 14-kDa secreted protein purified from Mycobacterium avium subsp. paratuberculosis . Scandinavian Journal of Immunology 2001; 53: 198–203.CrossRefGoogle ScholarPubMed
77. Vannuffel, P, et al. Occurrence, in Crohn's disease, of antibodies directed against a species-specific recombinant polypeptide of Mycobacterium paratuberculosis . Clinical and Diagnostic Laboratory Immunology 1994; 1: 241–243.CrossRefGoogle ScholarPubMed
78. Bach, H, et al. Immunogenicity of Mycobacterium avium subsp. paratuberculosis proteins in Crohn's disease patients. Scandinavian Journal of Gastroenterology 2011; 46: 30–39.CrossRefGoogle ScholarPubMed
79. Lee, A, et al. Association of Mycobacterium avium subspecies paratuberculosis With Crohn Disease in pediatric patients. Journal of Pediatric Gastroenterology and Nutrition 2011; 52: 170–174.CrossRefGoogle ScholarPubMed
80. Nakase, H, et al. Specific antibodies against recombinant protein of insertion element 900 of Mycobacterium avium subspecies paratuberculosis in Japanese patients with Crohn's disease. Inflammatory Bowel Diseases 2006; 12: 62–69.CrossRefGoogle ScholarPubMed
81. Kobayashi, K, et al. Serum antibodies to mycobacterial antigens in active Crohn's disease. Gastroenterology 1988; 94: 1404–1411.CrossRefGoogle ScholarPubMed
82. Walmsley, RS, et al. Antibodies against Mycobacterium paratuberculosis in Crohn's disease. QJM 1996; 89: 217–221.CrossRefGoogle ScholarPubMed
83. Verdier, J, et al. Specific IgG response against Mycobacterium avium paratuberculosis in children and adults with Crohn's disease. PLoS ONE 2013; 8: e62780.CrossRefGoogle ScholarPubMed
84. McFadden, JJ, Houdayer, C. No evidence for antibodies to mycobacterial A60 antigen in Crohn's disease sera by enzyme-linked immunoabsorbent assay (ELISA). Journal of Medical Microbiology 1988; 25: 295–298.CrossRefGoogle ScholarPubMed
85. Juste, RA, et al. Association between Mycobacterium avium subsp. paratuberculosis DNA in blood and cellular and humoral immune response in inflammatory bowel disease patients and controls. International Journal of Infectious Diseases 2009; 13: 247–254.CrossRefGoogle ScholarPubMed
86. Ebert, EC, et al. Induction of suppressor cells by Mycobacterium paratuberculosis antigen in inflammatory bowel disease. Clinical and Experimental Immunology 1991; 83: 320–325.CrossRefGoogle ScholarPubMed
87. Olsen, I, et al. Isolation of Mycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of Crohn's disease patients. PLoS ONE 2009; 4: e5641.CrossRefGoogle ScholarPubMed
88. Campos, N, et al. Macrophages from IBD patients exhibit defective tumour necrosis factor-alpha secretion but otherwise normal or augmented pro-inflammatory responses to infection. Immunobiology 2011; 216: 961–970.CrossRefGoogle ScholarPubMed
89. Sibartie, S, et al. Mycobacterium avium subsp. paratuberculosis (MAP) as a modifying factor in Crohn's disease. Inflammatory Bowel Diseases 2010; 16: 296–304.Google ScholarPubMed
90. Clancy, R, et al. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion. Digestive and Liver Diseases 2007; 39: 445–451.CrossRefGoogle ScholarPubMed
91. Singh, AV, et al. Evaluation of ‘indigenous absorbed ELISA kit’ for the estimation of seroprevalence of Mycobacterium avium subspecies paratuberculosis antibodies in human beings in North India. ISRN Veterinary Science 2011; 2011: 636038.CrossRefGoogle ScholarPubMed
92. Rosu, V, et al. Specific immunoassays confirm association of Mycobacterium avium subsp. paratuberculosis with type-1 but not type-2 diabetes mellitus. PLoS One 2009; 4: e4386.CrossRefGoogle Scholar
93. Bitti, ML, et al. Mycobacterium avium subsp. paratuberculosis in an Italian cohort of type 1 diabetes pediatric patients. Clinical and Developmental Immunology 2012; 2012: 785262.Google Scholar
94. Naser, SA, et al. Exploring the role of Mycobacterium avium subspecies paratuberculosis in the pathogenesis of type 1 diabetes mellitus: a pilot study. Gut Pathogens 2013; 5: 14.CrossRefGoogle ScholarPubMed
95. Masala, S, et al. Sardinian type 1 diabetes patients, transthyretin and Mycobacterium avium subspecies paratuberculosis infection. Gut Pathogens 2012; 4: 24.CrossRefGoogle ScholarPubMed
96. Cossu, A, et al. Antibodies recognizing specific Mycobacterium avium subsp. paratuberculosis's MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine. Cytokine 2013; 61: 337–339.CrossRefGoogle ScholarPubMed
97. Cossu, A, et al. MAP3738c and MptD are specific tags of Mycobacterium avium subsp. paratuberculosis infection in type I diabetes mellitus. Clinical Immunology 2011; 141: 49–57.CrossRefGoogle ScholarPubMed
98. Rani, PS, et al. Mycobacterium avium subsp. paratuberculosis is not discerned in diabetes mellitus patients in Hyderabad, India. International Journal of Medical Microbiology 2014; 304: 620–625 CrossRefGoogle Scholar
99. Cossu, D, et al. Anti Mycobacterium avium subsp. paratuberculosis heat shock protein 70 antibodies in the sera of Sardinian patients with multiple sclerosis. Journal of the Neurological Sciences 2013; 335: 131–133.Google ScholarPubMed
100. Frau, J, et al. Mycobacterium avium subsp. paratuberculosis and multiple sclerosis in Sardinian patients: epidemiology and clinical features. Multiple Sclerosis 2013; 19: 1437–1442.CrossRefGoogle ScholarPubMed
101. Cossu, D, et al. Association of Mycobacterium avium subsp. paratuberculosis with multiple sclerosis in Sardinian patients. PLoS ONE 2011; 6: e18482.CrossRefGoogle ScholarPubMed
102. Cossu, D, et al. Are Mycobacterium avium subsp. paratuberculosis and Epstein-Barr virus triggers of multiple sclerosis in Sardinia? Multiple Sclerosis 2012; 18: 1181–1184.CrossRefGoogle ScholarPubMed
103. Cossu, D, et al. Association of Mycobacterium avium subsp. paratuberculosis and SLC11A1 polymorphisms in Sardinian multiple sclerosis patients. Journal of Infection in Developing Countries 2013; 7: 203–207.Google ScholarPubMed
104. D'Amore, M, et al. Molecular identification of Mycobacterium avium subspecies paratuberculosis in an Italian patient with Hashimoto's thyroiditis and Melkersson-Rosenthal syndrome. Journal of Medical Microbiology 2010; 59: 137–139.Google Scholar
105. Masala, S, et al. Recognition of zinc transporter 8 and MAP3865c homologous epitopes by hashimoto's thyroiditis subjects from Sardinia: a common target with type 1 diabetes? PLoS ONE 2014; 9: e97621.Google ScholarPubMed
106. Rosu, V, et al. Mycobacterium avium subspecies paratuberculosis is not associated with type-2 diabetes mellitus. Annals of Clinical Microbiology and Antimicrobials 2008; 7: 9.Google Scholar
107. Richter, E, et al. Mycobacterium avium subsp. paratuberculosis infection in a patient with HIV, Germany. Emerging Infectious Diseases 2002; 8: 729–731.CrossRefGoogle Scholar
108. Naser, SA, et al. Occurrence of the IS900 gene in Mycobacterium avium complex derived from HIV patients. Molecular and Cellular Probes 1999; 13: 367–372.CrossRefGoogle ScholarPubMed
109. El-Zaatari, FA, et al. Identification of Mycobacterium avium complex in sarcoidosis. Journal of Clinical Microbiology 1996; 34: 2240–2245.CrossRefGoogle ScholarPubMed
110. Eishi, Y, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. Journal of Clinical Microbiology 2002; 40: 198–204.CrossRefGoogle ScholarPubMed
111. Lisby, G, Milman, N, Jacobsen, GK. Search for Mycobacterium paratuberculosis DNA in tissue from patients with sarcoidosis by enzymatic gene amplification. Acta Pathologica Microbiologica et Immunologica Scandinavica 1993; 101: 876–878.CrossRefGoogle ScholarPubMed
112. Ebrahim, S, Clarke, M. STROBE: new standards for reporting observational epidemiology, a chance to improve. International Journal of Epidemiology 2007; 36: 946–948.CrossRefGoogle ScholarPubMed
113. von Elm, E, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. British Medical Journal 2007; 335: 806–808.CrossRefGoogle ScholarPubMed
114. Vandenbroucke, JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Annals of Internal Medicine 2007; 147: W163–194.CrossRefGoogle ScholarPubMed
115. Del Prete, R, et al. Detection of Mycobacterium paratuberculosis in stool samples of patients with inflammatory bowel disease by IS900-based PCR and colorimetric detection of amplified DNA. Journal of Microbiological Methods 1998; 33: 105–114.CrossRefGoogle Scholar
116. Suenaga, K, et al. Serum antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease. Digestive Diseases and Sciences 1999; 44: 1202–1207.CrossRefGoogle ScholarPubMed
117. Kobayashi, K, Blaser, MJ, Brown, WR. Immunohistochemical examination for mycobacteria in intestinal tissues from patients with Crohn's disease. Gastroenterology 1989; 96: 1009–1015.CrossRefGoogle ScholarPubMed
118. Bannantine, JP, Bermudez, LE. No holes barred: invasion of the intestinal mucosa by Mycobacterium avium subsp. paratuberculosis . Infection and Immunity 2013; 81: 3960–3965.CrossRefGoogle ScholarPubMed
119. Bannantine, JP, et al. Complete genome sequence of Mycobacterium avium subsp. paratuberculosis, isolated from human breast milk. Genome Announcements 2014; 2: 10.1128/genomeA.01252-13.CrossRefGoogle Scholar
120. Singh, SV, et al. Genome sequence of the ‘Indian Bison Type’ biotype of Mycobacterium avium subsp. paratuberculosis strain S5. Genome Announcements 2013; 1: 10.1128/genomeA.00005-13122.CrossRefGoogle Scholar
121. Shankar, H, et al. Presence, characterization, and genotype profiles of Mycobacterium avium subspecies paratuberculosis from unpasteurized individual and pooled milk, commercial pasteurized milk, and milk products in India by culture, PCR, and PCR-REA methods. International Journal of Infectious Diseases 2010; 14: e121–6.CrossRefGoogle ScholarPubMed
122. Sohal, JS, et al. Genomic analysis of local isolate of Mycobacterium avium subspecies paratuberculosis . Veterinary Microbiology 2009; 134: 375–382.Google ScholarPubMed
123. Dohoo, I, Martin, W, Stryn, H (eds). Methods in Epidemiologic Research. VER Inc., Charlottetown, Prince Edward Island, Canada, 2012.Google Scholar
124. Matthews, N, et al. Agglutinins to bacteria in Crohn's disease. Gut 1980; 21: 376–380.CrossRefGoogle ScholarPubMed
125. Markesich, DC, et al. Investigations on etiology of Crohn's disease. Humoral immune response to stress (heat shock) proteins. Digestive Diseases and Sciences 1991; 36: 454–460.CrossRefGoogle ScholarPubMed
126. Elsaghier, A, et al. Antibodies to Mycobacterium paratuberculosis-specific protein antigens in Crohn's disease. Clinical & Experimental Immunology 1992; 90: 503–508.Google ScholarPubMed
127. Stainsby, KJ, et al. Antibodies to Mycobacterium paratuberculosis and nine species of environmental mycobacteria in Crohn's disease and control subjects. Gut 1993; 34: 371–374.CrossRefGoogle ScholarPubMed
128. Cohavy, O, et al. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infection and Immunity 1999; 67: 6510–6517.Google ScholarPubMed
129. Collins, MT, et al. Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. Journal of Clinical Microbiology 2000; 38: 4373–4381.CrossRefGoogle ScholarPubMed
130. Bernstein, CN, et al. Population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's disease and ulcerative colitis. Journal of Clinical Microbiology 2004; 42: 1129–1135.CrossRefGoogle ScholarPubMed
131. Bernstein, CN, et al. Testing the interaction between NOD-2 status and serological response to Mycobacterium paratuberculosis in cases of inflammatory bowel disease. Journal of Clinical Microbiology 2007; 45: 968–971.CrossRefGoogle ScholarPubMed
132. Polymeros, D, et al. Does cross-reactivity between Mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn's disease? Gastroenterology 2006; 131: 85–96.CrossRefGoogle ScholarPubMed
133. Singh, AV, et al. Presence and characterization of Mycobacterium avium subspecies paratuberculosis from clinical and suspected cases of Crohn's disease and in the healthy human population in India. International Journal of Infectious Diseases 2008; 12: 190–197.CrossRefGoogle ScholarPubMed
134. Di Sabatino, A, et al. Detection of Mycobacterium avium subsp. paratuberculosis (MAP)-specific IS900 DNA and antibodies against MAP peptides and lysate in the blood of Crohn's disease patients. Inflammatory Bowel Disease 2011; 17: 1254–1255.CrossRefGoogle ScholarPubMed
135. Biet, F, et al. Serum antibodies to Mycobacterium avium subspecies paratuberculosis combined with anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients: prevalence and diagnostic role. Digestive Diseases and Sciences 2011; 56: 1794–1800.CrossRefGoogle ScholarPubMed
136. Rowbotham, DS, Howdle, PD, Trejdosiewicz, LK. Peripheral cell-mediated immune response to mycobacterial antigens in inflammatory bowel disease. Clinical and Experimental Immunology 1995; 102: 456–461.CrossRefGoogle ScholarPubMed
137. Dalton, HR, Hoang, P, Jewell, DP. Antigen induced suppression in peripheral blood and lamina propria mononuclear cells in inflammatory bowel disease. Gut 1992; 33: 324–330.CrossRefGoogle ScholarPubMed
138. Ren, Z, et al. Selective Th2 pattern of cytokine secretion in Mycobacterium avium subsp. paratuberculosis infected Crohn's disease. Journal of Gastroenterology and Hepatology 2008; 23: 310–314.CrossRefGoogle ScholarPubMed
139. Netea, MG, et al. Defective acute inflammation in Crohn's disease. Lancet 2006; 368: 577–578.CrossRefGoogle ScholarPubMed
140. Reid, JD, Chiodini, RJ. Serologic reactivity against Mycobacterium paratuberculosis antigens in patients with sarcoidosis. Sarcoidosis 1993; 10: 32–35.Google ScholarPubMed
Figure 0

Fig. 1. Flow chart describing the movement of 3560 citations, the exclusion of 3432 and the inclusion of 128 studies through the systematic review process. HIV, Human immunodeficiency virus; T1DM/T2DM, diabetes mellitus type 1/type 2; CC, case-control study; CR case report or case series.

Figure 1

Table 1. Summary of findings: association of direct detection of Mycobacterium paratuberculosis and Crohn's disease in humans

Figure 2

Table 2. Summary of findings: association of Mycobacterium paratuberculosis and Crohn's disease in humans by ELISA

Figure 3

Table 3. Summary of findings: association of Mycobacterium paratuberculosis and Crohn's disease in humans using lymphocyte/cytokine assays

Figure 4

Table 4. Summary of findings: association of Mycobacterium paratuberculosis and diseases other than Crohn's disease in humans

Figure 5

Fig. 2. Random-effects meta-analysis of 16 case-control studies (I2 = 81%) that examined the association of immune reactions measured by ELISA to M. paratuberculosis in Crohn's disease patients compared to controls. MAP, M. paratuberculosis; PPD, purified protein derivative; PPA, protoplasmic antigen, HSP, heat shock protein; AHP, alkyl hydroperoxide reductase; GSD, glycosyl transferase; HBHA, heparin-binding haemagglutinin.

Figure 6

Table 5. Summary of findings: association of Mycobacterium paratuberculosis and Crohn's disease in humans by non-case-control study design

Figure 7

Table 6. Summary of findings: molecular epidemiology evidence for the relatedness of Mycobacterium paratuberculosis from various animal species and humans

Supplementary material: File

Waddell supplementary material

Appendix 1

Download Waddell supplementary material(File)
File 309.5 KB